Genentech’s Tecentriq-Avastin Combo Flops in Ovarian Cancer Trial

Genentech announced that its cancer blockluster Tecentriq (atezolizimab) failed a phase 3 trial in combination with Avastin (bevacizumab), paclitaxel and carboplatin for treatment of ovarian cancer.

The trial evaluated the combination therapy in women with stage three or four ovarian cancer who were undergoing either pre- or post-surgery adjuvant chemotherapy.

The company said the treatment regimen did not meet its target outcome of progression-free survival.